Acer Therapeutics Inc.
DelistedCIK 1069308fmd_14ZHE5JSZ4C88ENQ5E839M4WSHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2004 to Sep 30, 2023, 60 periods
Latest annual · FY2021
Millions- Total revenues
- 1
- Operating income
- (25)
- Net income
- (26)
- Free cash flow
- (30)
Latest quarter · Q3 FY2023
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (13)
- Net income
- (15)
- Free cash flow
- (14)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2018 to FY2021
- n/m
- Net income, 5 yearsFY2017 to FY2022
- n/m
Acer Therapeutics Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -$24.6 million | -$15.9 million | 10-K 2023-03-27 · proof | |
| Net income | -$26.2 million | -$15.4 million | 10-K 2023-03-27 · proof | |
| Cash from operating activities | -$30.3 million | -$134,909 | 10-K 2023-03-27 · proof | |
| Free cash flow | -$30.4 million | -$189,853 | 10-K 2023-03-27 · proof | |
| Total assets | $11.6 million | $36.3 million | -67.9% | 10-K 2023-03-27 · proof |
| Total liabilities | $28.4 million | $38 million | -25.3% | 10-K 2023-03-27 · proof |
| Cash and cash equivalents | $2.3 million | $12.7 million | -81.7% | 10-K 2023-03-27 · proof |
- What was Acer Therapeutics Inc.'s operating income in fiscal 2022?
- Acer Therapeutics Inc. reported operating income of -$24.6 million for fiscal 2022 (the year ended Dec 31, 2022), against -$15.9 million the year before. Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
- What was Acer Therapeutics Inc.'s net income in fiscal 2022?
- Acer Therapeutics Inc. reported net income of -$26.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$15.4 million the year before. Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
- What was Acer Therapeutics Inc.'s cash from operating activities in fiscal 2022?
- Acer Therapeutics Inc. reported cash from operating activities of -$30.3 million for fiscal 2022 (the year ended Dec 31, 2022), against -$134,909 the year before. Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
- What was Acer Therapeutics Inc.'s free cash flow in fiscal 2022?
- Acer Therapeutics Inc. reported free cash flow of -$30.4 million for fiscal 2022 (the year ended Dec 31, 2022), against -$189,853 the year before. Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
- What are Acer Therapeutics Inc.'s total assets?
- As of Dec 31, 2022, Acer Therapeutics Inc. reported total assets of $11.6 million, against $36.3 million a year earlier (-67.9%). Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
- What are Acer Therapeutics Inc.'s total liabilities?
- As of Dec 31, 2022, Acer Therapeutics Inc. reported total liabilities of $28.4 million, against $38 million a year earlier (-25.3%). Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
- What are Acer Therapeutics Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, Acer Therapeutics Inc. reported cash and cash equivalents of $2.3 million, against $12.7 million a year earlier (-81.7%). Source: the 10-K filed with the SEC on Mar 27, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1069308&period_type=annual&limit=5"Information only, not investment advice.